

In the Claims:

Please withdraw Claims 7-21, 23-24, and 26-33 without prejudice. A listing of the remaining original Claims and status of all the Claims follows:

Claim 1 (Original): A therapeutic combination comprising an amount of a COX-2 inhibitor compound source and an amount of a sex steroid compound wherein the amount of a COX-2 inhibitor compound source and the amount of the sex steroid compound together comprises a dysmenorrhea-effective amount of the compounds.

Claim 2 (Original): The combination of Claim 1 wherein the COX-2 inhibitor source is a COX-2 inhibitor.

Claim 3 (Original): The combination of Claim 2 wherein the COX-2 inhibitor is a tricyclic COX-2 inhibitor.

Claim 4 (Original): The combination of Claim 3 wherein the tricyclic COX-2 inhibitor is selected from the group consisting of a pyrazole COX-2 inhibitor, a furanone COX-2 inhibitor, an isoxazole COX-2 inhibitor, a pyridine COX-2 inhibitor, and a pyridazinone COX-2 inhibitor.

Claim 5 (Original): The combination of Claim 4 wherein the tricyclic COX-2 inhibitor is a pyrazole COX-2 inhibitor.

Claim 6 (Original): The combination of Claim 5 wherein the tricyclic COX-2 inhibitor is celecoxib.

Claims 7-21 (Withdrawn)

Claim 22 (Original): The combination of Claim 1 wherein the sex steroid compound is an estrogen sex steroid.

Claims 23-24 (Withdrawn)

Claim 25 (Original): The combination of Claim 24 wherein the estrogen sex steroid is ethinyl estradiol.

Claims 26-33 (Withdrawn)

Claim 34 (Original): The combination of Claim 1 wherein the COX-2 inhibitor compound source and the sex steroid compound are present in a single composition.

Claims 35-55 (Withdrawn)